AbbVie's Telisotuzumab Adizutecan Receives Two FDA Breakthrough Therapy Designations for Colorectal and Lung Cancers

The U.S. Food and Drug Administration (FDA) has granted two Breakthrough Therapy Designations (BTDs) to AbbVie's investigational antibody-drug conjugate, telisotuzumab adizutecan (Temab-A). These designations are for its use in refractory, metastatic colorectal cancer (in combination with bevacizumab) and as a monotherapy for locally advanced or metastatic EGFR wild-type, c-Met protein-expressing, non-squamous non-small cell lung cancer.